Drug Trial Radar · NCT00673205
(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Dec 10, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,588
Actual
Start
Sep 1995
Primary completion
Aug 2008
Study completion Aug 2008
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 7, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.
Conditions
- Non-Metastatic Prostate Cancer
Interventions
BicalutamideDrug
150mg p.o. daily
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to clinical progressionTime frame: Throughout study period
- Tolerability in terms of adverse events and laboratory parametersTime frame: Throughout study period
Locations
128 sites in 16 countries. Site status is shown where the registry gives one.
Research Site
Wooloongabba, Queensland, Australia
Research Site
East Melbourne, Victoria, Australia
Research Site
Graz, Austria
Research Site
Linz, Austria
Research Site
Mistelbach, Austria
Research Site
Oberwart, Austria
Research Site
Sankt Pölten, Austria
Research Site
Antwerp, Belgium
Research Site
Bruges, Belgium
Research Site
Brussels, Belgium
Research Site
Ghent, Belgium
Research Site
Kortrijk, Belgium
Research Site
Leuven, Belgium
Research Site
Mons, Belgium
Research Site
Ostend, Belgium
Research Site
Seraing, Belgium
Research Site
Brno, Czechia
Research Site
Hradec Králové, Czechia
Research Site
Olomouc, Czechia
Research Site
Prague, Czechia
Research Site
Berlin, Germany
Research Site
Bonn, Germany
Research Site
Dresden, Germany
Research Site
Freiburg im Breisgau, Germany
Research Site
Heidelberg, Germany
Research Site
Jena, Germany
Research Site
Lübeck, Germany
Research Site
Lüdenscheid, Germany
Research Site
Mannheim, Germany
Research Site
München, Germany
Research Site
Regensburg, Germany
Research Site
Sigmaringen, Germany
Research Site
Budapest, Hungary
Research Site
Miskolc, Hungary
Research Site
Nyíregyháza, Hungary
Research Site
Dublin, Ireland
Research Site
Haifa, Israel
Research Site
Petah Tikva, Israel
Research Site
Tel Aviv, Israel
Research Site
Tel HaShomer, Israel
Showing 40 of 128 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.